Cyproterone Acetate - Comprehensive Research Paper

Document Information

• Paper Number: 54 of 76
• Category: Anti-Androgens - Steroidal Antiandrogen/Progestin
• Last Updated: 2025-12-26
• Status: NOT FDA-APPROVED (available outside US)

1. Summary

Cyproterone acetate (CPA) is a potent steroidal antiandrogen and progestin that represents one of the most effective androgen-blocking medications available globally. First synthesized in 1961 and marketed since the 1970s, CPA combines powerful androgen receptor antagonism with progestogenic activity that suppresses gonadotropin release, creating dual mechanisms for testosterone reduction. Despite widespread use in Europe, Canada, Australia, and elsewhere for conditions including prostate cancer, hirsutism, acne, and transgender hormone therapy, CPA has never been approved by the US FDA due to concerns about hepatotoxicity and tumor risks observed in animal studies.

The 2020 European Medicines Agency warning regarding dose-dependent meningioma risk has fundamentally changed CPA prescribing patterns, leading to reduced dosing and more careful patient selection. At cumulative doses exceeding 36 grams, meningioma risk increases 11-fold, though low-dose formulations (1-2 mg combined with ethinylestradiol) appear safe. Recent 2024 research suggests that lower doses may be as effective as traditional higher doses for testosterone suppression, supporting the trend toward dose minimization.

Key Distinguishing Features:

• Most potent steroidal antiandrogen - Stronger AR blockade than spironolactone
• Dual mechanism - AR antagonism plus gonadotropin suppression
• NOT available in United States - FDA never approved
• Meningioma risk - Dose-dependent; EMA restrictions since 2020
• Highly effective for prostate cancer, hirsutism, transgender care

Key Characteristics:

• Generic Name: Cyproterone acetate (CPA)
• Brand Names: Androcur (monotherapy), Diane-35/Dianette (with ethinylestradiol)
• FDA Approval: NOT FDA-APPROVED (never introduced in US)
• Drug Class: Steroidal antiandrogen, progestin
• Primary Mechanisms: Androgen receptor antagonist, progestogenic antigonadotropin
• Potency: IC50 = 7.1 nM at androgen receptor
• Half-Life: 1.5-2 days (parent); 3-4 days (active metabolite)
• Controlled Substance: No
• Pregnancy Category: X (teratogenic - feminizes male fetus)
• Available Formulations: Tablets (10, 50, 100 mg), combined with EE (2 mg + 35 mcg)

Primary Clinical Applications (Outside US):

• Prostate cancer (advanced)
• Hirsutism and hyperandrogenism
• Severe acne unresponsive to other treatments
• Transgender feminizing hormone therapy
• Sexual deviation/paraphilias (in some countries)
• Precocious puberty (males)

Goal Relevance:

• Managing advanced prostate cancer by reducing testosterone levels to slow cancer progression.
• Reducing excessive hair growth (hirsutism) in women for improved skin appearance and confidence.
• Alleviating severe acne that hasn't responded to other treatments for clearer skin.
• Supporting transgender women in their hormone therapy journey for effective feminization.
• Addressing sexual health concerns related to high testosterone levels, such as reducing unwanted sexual urges.
• Managing symptoms of precocious puberty in young boys to delay early onset puberty changes.

Goal Archetype Integration

CPA serves multiple therapeutic archetypes due to its dual mechanism combining potent androgen receptor antagonism with progestogenic gonadotropin suppression.

Anti-Androgen Archetype

Primary Mechanism: Direct androgen receptor blockade

Goal Alignment:

• Block testosterone and DHT at target tissues
• Reduce androgen-mediated effects (hair growth, sebum, prostate stimulation)
• Effective even when testosterone levels remain elevated (AR blockade)

Archetype Characteristics:

Best For:

• Rapid androgen blockade needed
• Patients not responding to weaker antiandrogens
• Target tissue effects primary goal (vs. systemic T reduction)

Progestin Archetype

Primary Mechanism: Hypothalamic-pituitary axis suppression via progesterone receptor activation

Goal Alignment:

• Suppress LH/FSH release from pituitary
• Reduce gonadal testosterone production (50-80%)
• Provide dual-mechanism testosterone control

Archetype Characteristics:

Best For:

• Comprehensive testosterone suppression needed
• Combination with estrogen therapy
• Patients requiring both T suppression and AR blockade

Feminizing HRT Archetype

Primary Mechanism: Combined testosterone suppression + AR blockade enabling estrogen-dominant physiology

Goal Alignment:

• Suppress testosterone to female physiologic range (<50 ng/dL)
• Block residual androgen activity at tissues
• Support estrogen-mediated feminization
• Enable breast development, fat redistribution, skin changes

Archetype Characteristics:

Protocol Position:

• First-line antiandrogen outside US (alternative to spironolactone)
• Combined with estradiol (oral, transdermal, or injectable)
• 2024 evidence supports low doses (10-12.5 mg/day)
• Can discontinue after orchiectomy

Feminization Timeline with CPA + Estradiol:

Multi-Archetype Considerations

Advantages of Dual Mechanism:

• More complete androgen suppression than single-mechanism agents
• Effective at lower doses for T suppression
• Faster onset than AR-only antagonists

Disadvantages:

• Cannot isolate one mechanism without the other
• Progestogenic effects may be unwanted (mood, weight)
• Higher risk profile than single-mechanism alternatives

2. Mechanism of Action

Cyproterone acetate exerts its antiandrogen effects through multiple complementary mechanisms, making it one of the most comprehensive testosterone-blocking agents available.

Androgen Receptor Antagonism

Direct AR Blockade:

• Competitive antagonist at androgen receptor
• IC50 = 7.1 nM (high affinity)
• Blocks testosterone and DHT binding
• More potent than spironolactone at AR
• Prevents androgen-mediated gene transcription

Tissue Effects:

• Reduces sebum production (sebaceous glands)
• Decreases hair follicle stimulation
• Blocks androgen effects on prostate
• Facilitates feminization (transgender care)

Progestogenic Activity (Antigonadotropic)

Hypothalamic-Pituitary Suppression:

• Potent progestogen with significant activity
• Suppresses GnRH release from hypothalamus
• Reduces LH secretion from pituitary
• Decreases FSH secretion
• Results in reduced gonadal testosterone production

Gonadal Effects:

• Testosterone production decreases 50-80%
• More effective T suppression than pure AR antagonists
• Synergistic with AR blockade for total androgen effect

5α-Reductase Inhibition

DHT Reduction:

• Inhibits conversion of testosterone to DHT
• Reduces more potent androgen at tissue level
• Contributes to anti-androgenic effect
• Less well characterized than finasteride/dutasteride

Additional Receptor Activities

Glucocorticoid Receptor:

• Weak glucocorticoid agonist activity
• May cause mild cortisol-like effects at high doses
• Can suppress ACTH at very high doses

Progesterone Receptor:

• Strong agonist activity
• Contributes to gonadotropin suppression
• Causes progestogenic side effects

Mineralocorticoid/Estrogen:

• Minimal activity at these receptors

Mechanism Comparison

Dose-Response Relationship

Low Doses (1-2 mg/day with EE):

• Primarily AR antagonism
• Minimal gonadotropin suppression
• Used in combination OCPs

Moderate Doses (10-50 mg/day):

• Combined AR blockade and T suppression
• Effective for hirsutism, transgender therapy
• 2024 research supports efficacy at lower end

High Doses (100-300 mg/day):

• Maximum testosterone suppression
• Used for prostate cancer
• Highest risk of adverse effects

Metabolic Pathway

Primary Metabolism:

• Hepatic metabolism (extensive)
• Reduction, hydroxylation, conjugation
• Active metabolite: 15β-hydroxycyproterone acetate
• CYP3A4 involved

Pharmacokinetic Note:

• Parent half-life: 1.5-2 days
• Active metabolite half-life: 3-4 days
• Allows once-daily dosing
• Accumulation with repeated dosing

3. Clinical Indications

Prostate Cancer (Advanced/Metastatic)

Mechanism in Prostate Cancer:

• Androgen deprivation central to treatment
• CPA provides complete androgen blockade as monotherapy
• Blocks AR and suppresses T production

Historical Use:

• One of first antiandrogens for prostate cancer
• Monotherapy option in some countries
• Combined with GnRH agonists to prevent flare
• Largely replaced by newer agents in many settings

Dosing:

• 100-300 mg/day in divided doses
• May use as monotherapy or adjunctive
• High doses associated with more toxicity

Hirsutism and Hyperandrogenism

Primary Indication Outside US:

• First-line antiandrogen in many countries
• Highly effective for reducing hair growth
• Often combined with oral contraceptive

Efficacy:

• Superior to placebo in RCTs
• Comparable to other antiandrogens
• Response at 6-12 months
• Hair becomes finer, grows slower

Dosing for Hirsutism:

• Traditional: 50-100 mg days 5-15 of cycle (reverse sequential)
• Modern trend: 10-25 mg/day (lower doses)
• Combined with EE 35 mcg (Diane-35)
• 2 mg CPA + EE may be sufficient for mild cases

Acne (Severe, Female)

Mechanism:

• Reduces sebum production
• Addresses hormonal component
• Particularly effective for hormonal acne

Indications:

• Severe acne unresponsive to standard therapies
• Acne with signs of hyperandrogenism
• Female patients only (teratogenic)

Dosing:

• Diane-35 (2 mg CPA + 35 mcg EE) often sufficient
• Higher doses rarely needed for acne alone

Transgender Feminizing Hormone Therapy

Role in Gender-Affirming Care:

• Widely used outside US (primary alternative to spironolactone)
• Effective testosterone suppression
• Combined with estradiol

Advantages:

• More potent than spironolactone
• Better T suppression (gonadotropin pathway)
• Once-daily dosing

Disadvantages:

• Meningioma risk (dose-dependent)
• Hepatotoxicity potential
• Depression/mood effects
• Not available in US

Dosing (Current Recommendations):

• Traditional: 25-50 mg/day
• 2024 trend: 10-12.5 mg/day (equally effective for T suppression)
• Lowest effective dose recommended due to meningioma risk

Precocious Puberty (Male)

Use:

• Suppresses testosterone production
• Delays pubertal development
• Specialist use only

Paraphilias/Sexual Deviation

Use in Some Jurisdictions:

• Reduces libido and sexual urges
• "Chemical castration" in forensic settings
• Ethically controversial
• Not used in all countries

5. Dosing and Administration

Dosage Forms

Monotherapy (Androcur or generic):

• 10 mg tablets
• 50 mg tablets
• 100 mg tablets

Combined with Ethinylestradiol:

• Diane-35/Dianette: 2 mg CPA + 35 mcg EE
• Various brand names globally

Condition-Specific Dosing

Prostate Cancer:

• 100-300 mg/day in 2-3 divided doses
• Often combined with GnRH agonist initially
• Long-term treatment

Hirsutism (Traditional):

• Reverse sequential: 50-100 mg days 5-14 or 5-15 of cycle
• Combined with OCP (EE-containing)
• Re-evaluate at 6-12 months

Hirsutism (Current Trend):

• Lower doses: 10-25 mg/day
• Continuous or cyclical
• Combined with EE (Diane-35) or separate OCP

Transgender Feminizing (Updated):

• Traditional: 25-50 mg/day
• 2024 evidence-based: 10-12.5 mg/day may be equally effective
• Combined with estradiol
• Goal: Testosterone suppression to female range
• Lowest effective dose due to meningioma risk

Severe Acne:

• Diane-35 (2 mg CPA + 35 mcg EE) usually sufficient
• Higher doses rarely needed

Precocious Puberty:

• Weight-based dosing under specialist supervision
• Variable protocols

Administration

Timing:

• May take with or without food
• Once daily for doses ≤50 mg
• Divided doses for higher amounts
• Consistent timing recommended

Cyclical vs. Continuous:

• Cyclical: Days 5-14 or 5-15 (with OCP)
• Continuous: Daily without cycling
• Both approaches used depending on indication

Duration of Treatment

Hirsutism:

• Minimum 6-12 months for visible effect
• Often continued long-term
• Hair regrows after discontinuation

Transgender:

• Long-term until orchiectomy (if desired)
• May discontinue after orchiectomy
• Regular monitoring while on therapy

Prostate Cancer:

• Typically long-term or until progression
• May be used intermittently

Dose Optimization (2024 Evidence)

Low-Dose Efficacy:

• Recent studies show 10-12.5 mg/day as effective as 25-50 mg for T suppression
• EMA and experts recommend lowest effective dose
• Reduces meningioma and other risks
• Standard of care shifting toward lower doses

Age-Stratified Dosing

Rationale for Age-Based Adjustments

CPA dosing should be individualized based on age due to:

• Altered hepatic metabolism in older adults
• Cumulative meningioma risk over time
• Different gonadal function by age group
• Varying therapeutic goals across life stages

Core Principle: Lower doses are safer and often equally effective. The trend toward dose minimization is supported by 2024 evidence and EMA recommendations.

Age Group Recommendations

Young Adults (18-30 years)

Transgender Feminizing:

Rationale:

• Excellent gonadal function allows low-dose effectiveness
• Highest lifetime cumulative exposure risk
• Progestogenic effects (breast development) achievable at low doses
• Depression risk warrants conservative dosing

Hirsutism/Acne:

• Diane-35 (2 mg CPA + 35 mcg EE) often sufficient
• Add 10-25 mg CPA only if inadequate response
• Re-evaluate need every 6-12 months

Middle-Aged Adults (31-50 years)

Transgender Feminizing:

Key Considerations:

• Baseline MRI recommended before initiating at doses >=10 mg/day
• More vigilant hepatic monitoring due to accumulated exposures
• May require slightly higher doses for T suppression vs. younger patients
• Depression screening critical (peak incidence age group)

Prostate Cancer:

• Doses 100-200 mg/day may be used
• Hepatic monitoring intensified
• Baseline and periodic brain MRI
• Cardiovascular risk assessment

Older Adults (51-65 years)

Transgender Feminizing:

Key Considerations:

• Reduced hepatic clearance - lower doses may achieve equivalent effect
• Higher baseline meningioma risk (age-related)
• VTE risk elevated - consider alternatives or enhanced anticoagulation awareness
• More frequent LFT monitoring recommended
• Depression/cognitive effects may be more pronounced

Prostate Cancer:

• Careful risk-benefit assessment
• Lower doses (50-100 mg/day) may be sufficient
• GnRH agonists may be preferred for safety profile
• Enhanced cardiovascular monitoring

Elderly (>65 years)

General Recommendation: Use with extreme caution; prefer alternatives when possible.

Risk Factors in Elderly:

• Hepatic function decline (reduce all doses by 25-50%)
• Cumulative meningioma risk
• VTE risk significantly elevated
• Polypharmacy concerns
• Cognitive effects of antiandrogen therapy

Cumulative Dose Tracking

Critical Safety Metric: Track lifetime cumulative CPA exposure

Calculating Cumulative Dose:

Cumulative dose (g) = Daily dose (mg) x Days of use / 1000

Example: 25 mg/day for 4 years
= 25 x (365 x 4) / 1000 = 36.5 g (HIGH RISK threshold)

Example: 10 mg/day for 4 years
= 10 x (365 x 4) / 1000 = 14.6 g (MODERATE risk)

Low-Dose Safety Evidence

2024 Research Summary:

• 10-12.5 mg/day achieves equivalent T suppression to 25-50 mg/day
• Lower doses associated with:
  • Reduced hepatotoxicity incidence
  • Lower depression rates
  • Decreased meningioma risk
  • Similar feminization outcomes
  • Better long-term tolerability

EMA 2020 Recommendations:

• Use lowest effective dose
• Doses >=10 mg/day only when alternatives have failed
• Regular re-evaluation of treatment necessity
• Low-dose combinations (1-2 mg with EE) not restricted

6. Pharmacokinetics

Absorption

Oral Bioavailability:

• Approximately 88%
• Well absorbed from GI tract
• Complete absorption

Time to Peak (Tmax):

• 2-4 hours after oral administration
• Food has minimal effect on absorption

Distribution

Protein Binding:

• Approximately 96% bound to plasma proteins
• Primarily albumin (not SHBG-bound)
• Good tissue distribution

Volume of Distribution:

• Moderate tissue distribution
• Crosses blood-brain barrier
• Crosses placenta (teratogenic)
• Enters breast milk

Metabolism

Hepatic Metabolism:

• Extensive first-pass metabolism
• Multiple metabolic pathways
• Hydroxylation, deacetylation, conjugation
• CYP3A4 involved

Active Metabolite:

• 15β-hydroxycyproterone acetate
• Pharmacologically active
• Longer half-life than parent

Metabolites:

• Multiple hydroxylated forms
• Glucuronide conjugates
• Some with antiandrogen activity

Elimination

Half-Life:

• Parent drug: 1.5-2 days (38-42 hours)
• 15β-hydroxy metabolite: 3-4 days
• Allows once-daily dosing
• Accumulation occurs with repeated dosing

Excretion:

• Primarily fecal (~60%)
• Urinary (~30%)
• Mostly as metabolites
• <1% unchanged in urine

Steady State

Time to Steady State:

• Approximately 10-14 days
• Due to long half-life
• Accumulation factor ~2-3x

Special Populations

Hepatic Impairment:

• Extensively metabolized in liver
• Contraindicated in severe liver disease
• Prolonged half-life in liver dysfunction

Renal Impairment:

• Minimal renal excretion of parent drug
• No specific dose adjustment required
• Metabolites may accumulate

Elderly:

• May have altered metabolism
• Consider lower doses
• Monitor closely

7. Side Effects and Adverse Reactions

Meningioma (Critical Safety Issue)

EMA 2020 Warning:

• Dose-dependent increased risk
• At cumulative doses ≥36g: 11-fold increased risk
• Risk at doses ≥25 mg/day established
• Low-dose (1-2 mg with EE): No increased risk demonstrated

Risk by Dose/Duration:

Clinical Implications:

• Use lowest effective dose
• MRI recommended before high-dose initiation
• Permanent discontinuation if meningioma detected
• Most meningiomas regress after CPA cessation

Hepatotoxicity (Major Concern)

Patterns:

• Hepatocellular injury most common
• Cholestatic hepatitis reported
• Fulminant hepatic failure rare but reported
• Mostly at high doses (200-300 mg/day)

Risk Factors:

• High doses (prostate cancer treatment)
• Pre-existing liver disease
• Concurrent hepatotoxic drugs
• Alcohol abuse

2021 Fatal Case Report:

• 25 mg/day in young woman for hirsutism
• Rare at low doses but can occur
• Monitoring recommended

Monitoring:

• Baseline LFTs
• Periodic LFTs during treatment
• Discontinue if significant elevation

Common Side Effects

Endocrine/Hormonal:

• Decreased libido (common, dose-related)
• Erectile dysfunction (males)
• Feminization (intended in transgender, unwanted in males)
• Breast tenderness/enlargement
• Amenorrhea (intended effect in most uses)
• Fatigue

Psychiatric:

• Depression (significant concern)
• Mood changes
• Anxiety
• Fatigue, lethargy

Metabolic:

• Weight gain
• Changes in lipid profile
• Glucose intolerance (rare)

Cardiovascular:

• Venous thromboembolism (especially with EE)
• Fluid retention

Serious Adverse Reactions

Thromboembolic Events:

• DVT, PE risk increased
• Especially when combined with EE
• Use caution in patients with VTE risk factors

Adrenal Suppression:

• High doses may suppress ACTH
• Glucocorticoid-like effects
• May require stress-dose steroids

Vitamin B12 Deficiency:

• Reported with long-term use
• Monitor in prolonged therapy

Comparison with Other Antiandrogens

8. Drug Interactions

CYP3A4 Interactions

CYP3A4 Inhibitors (Increase CPA Levels):

CYP3A4 Inducers (Decrease CPA Levels):

Hormonal Interactions

Estrogen Therapy:

• Commonly used together (transgender, hirsutism)
• No adverse pharmacokinetic interaction
• Additive VTE risk when combined

Other Antiandrogens:

• Additive antiandrogen effect
• May combine with finasteride
• Monitor for over-suppression

Hepatotoxicity-Focused Drug Interactions (Critical)

CPA carries significant hepatotoxic potential. Drug combinations affecting liver function require careful management.

High-Risk Hepatotoxic Combinations (AVOID)

Moderate-Risk Combinations (Use with Enhanced Monitoring)

Alcohol Interaction (Critical)

Mechanism: Alcohol potentiates CPA hepatotoxicity through:

• CYP2E1 induction increasing toxic metabolites
• Glutathione depletion reducing hepatoprotection
• Direct ethanol hepatotoxicity
• Synergistic mitochondrial dysfunction

Clinical Evidence:

• 2021 case report: Fatal hepatic failure in patient on CPA 25 mg/day with moderate alcohol use
• Hepatotoxicity risk increases exponentially with alcohol consumption

Recommendations:

Herbal/Supplement Interactions

Estradiol + CPA: Liver Considerations

Oral Estradiol:

• First-pass hepatic metabolism
• May slightly increase hepatic stress
• Combined with CPA: Monitor LFTs more frequently

Transdermal/Injectable Estradiol:

• Bypasses first-pass metabolism
• Preferred route when combined with CPA
• Reduced hepatic burden

Recommendation: For patients on CPA, prefer non-oral estradiol routes to minimize cumulative hepatic stress.

Other Interactions

Antidiabetic Agents:

• CPA may affect glucose tolerance
• Monitor blood glucose
• Adjust diabetic medications as needed

Warfarin:

• Potential interaction (variable)
• Monitor INR

Corticosteroids:

• CPA has weak glucocorticoid activity
• May have additive effects at high doses

9. Contraindications

Absolute Contraindications

Pregnancy:

• Category X (teratogenic)
• Feminizes male fetus
• Pregnancy must be excluded before initiation
• Effective contraception mandatory

Meningioma:

• Current or history of meningioma
• Must stop permanently if detected
• Screen before high-dose therapy

Severe Liver Disease:

• Active hepatitis
• Cirrhosis
• History of liver tumors
• Significant liver enzyme elevation

Thromboembolic Disorders:

• Active DVT/PE
• History of VTE (relative contraindication)
• Severe coagulation disorders

Hypersensitivity:

• Known allergy to CPA

Relative Contraindications

Depression:

• History of severe depression
• Monitor closely if used
• Consider alternatives

Sickle Cell Disease:

• Increased VTE risk
• Use with extreme caution

Diabetes Mellitus:

• May affect glucose tolerance
• Monitor blood glucose

Obesity:

• Increased VTE risk
• Weight gain side effect

Warnings and Precautions

Before Starting High-Dose Therapy:

• MRI brain to exclude meningioma
• Baseline LFTs
• Pregnancy test
• VTE risk assessment

During Therapy:

• Periodic LFT monitoring
• Depression screening
• Consider MRI if neurological symptoms

EMA Recommendations (2020):

• Doses ≥10 mg/day: Only after other options failed
• Lowest effective dose
• Regular re-evaluation of need for treatment

10. Special Populations

Pregnancy

Category: X (CONTRAINDICATED)

Risks:

• Feminizes male fetus
• Ambiguous genitalia
• Hypospadias
• Teratogenic at any dose

Requirements:

• Pregnancy test before initiation
• Effective contraception throughout treatment
• Stop immediately if pregnancy occurs

Lactation

Excretion:

• Enters breast milk (~0.2% of maternal dose)
• Antiandrogen effects possible in nursing infant

Recommendation:

• Contraindicated during breastfeeding
• Do not breastfeed while on CPA

Pediatric Use

Precocious Puberty:

• Used in specialist settings for male precocious puberty
• Limited data
• Weight-based dosing

Not Recommended:

• General pediatric use not recommended
• Specialist supervision only

Geriatric Use

Considerations:

• May have altered metabolism
• Higher risk of hepatic effects
• VTE risk increased with age
• Prostate cancer: May be used with monitoring

Hepatic Impairment

Contraindicated in Severe Liver Disease:

• Extensive hepatic metabolism
• Hepatotoxicity risk increased
• Avoid in cirrhosis
• LFT monitoring essential

Renal Impairment

Minimal Impact:

• Not primarily renally excreted
• No specific dose adjustment
• Use standard doses
• Monitor as usual

Transgender Women

Specific Considerations:

• Effective testosterone suppression
• Combine with estradiol
• 2024 evidence supports low doses (10-12.5 mg)
• Monitor for meningioma symptoms
• Depression screening important

Monitoring:

• Testosterone levels (goal: female range)
• LFTs
• Mental health assessment
• Consider brain MRI before prolonged high-dose use

Patients with Depression History

Increased Risk:

• CPA commonly causes mood effects
• Pre-existing depression may worsen
• Monitor closely
• Consider alternatives (bicalutamide, spironolactone)

11. Monitoring Parameters

Baseline Assessments

Before Initiating Therapy:

• Liver function tests (ALT, AST, bilirubin, ALP)
• Pregnancy test (mandatory in reproductive-age women)
• Depression screening
• VTE risk assessment
• Testosterone levels (for efficacy monitoring)
• Prolactin (optional)

Before High-Dose Therapy (≥25 mg/day):

• Brain MRI to exclude meningioma
• More extensive liver function evaluation
• Careful VTE risk assessment

During Therapy

Liver Function:

Additional Monitoring:

• Testosterone: At 3 months, then periodically
• Depression screening: Each visit
• Weight: Each visit
• Blood pressure: Each visit

Meningioma Surveillance

Who to Screen:

• Consider baseline MRI for doses ≥10 mg/day
• MRI if neurological symptoms develop
• Regular clinical assessment for symptoms

Symptoms Requiring Evaluation:

• Headaches (new or worsening)
• Visual changes
• Hearing changes
• Seizures
• Focal neurological deficits

When to Discontinue

Transgender-Specific Monitoring

Hormonal Goals:

• Testosterone: Target female range (<50 ng/dL)
• Estradiol: Target female range (100-200 pg/mL)
• Check levels at 3 months, then every 6-12 months

Safety Monitoring:

• LFTs: Standard schedule above
• Prolactin: Baseline and annually
• Mental health: Regular assessment
• Bone density: Consider after prolonged use

Bloodwork Impact

CPA significantly affects multiple laboratory parameters. Understanding expected changes versus concerning abnormalities is critical for safe monitoring.

Liver Function Tests (LFTs) - Critical Monitoring

Expected vs. Concerning Changes

LFT Monitoring Protocol

Baseline:

• Full hepatic panel before initiation
• If elevated, investigate before starting CPA
• Do not initiate if ALT/AST >2x ULN

During Therapy:

If LFT Abnormalities Detected:

Prolactin - CPA Raises Prolactin (Important)

Mechanism: CPA's progestogenic activity stimulates pituitary lactotroph proliferation, leading to hyperprolactinemia.

Prolactin Changes on CPA

Clinical Significance:

• Mild elevations (up to 50-60 ng/mL) are common and usually benign
• Moderate elevations (60-100 ng/mL) warrant investigation
• Marked elevations (>100 ng/mL) require pituitary imaging

Prolactin Monitoring Protocol:

Symptoms of Hyperprolactinemia:

• Galactorrhea (breast discharge)
• Gynecomastia (may be desired effect in transgender patients)
• Sexual dysfunction (decreased libido, erectile dysfunction)
• Menstrual irregularities (in those with ovarian function)
• Headaches, visual changes (if prolactinoma developing)

Management of Elevated Prolactin:

Important Note for Feminizing HRT:

• Some prolactin elevation may support breast development
• Balance between therapeutic benefit and safety
• Estradiol also raises prolactin; combined effect with CPA

Hormonal Panel Changes

Testosterone and Related Hormones

Testosterone Suppression Timeline:

Estradiol (When Combined with Estrogen Therapy)

Metabolic Panel Effects

Lipid Changes

Recommendation: Annual lipid panel; more frequent if baseline abnormalities.

Glucose Metabolism

Complete Blood Count (CBC) Effects

Electrolyte and Renal Effects

CPA has minimal direct renal effects (unlike spironolactone):

Recommended Comprehensive Bloodwork Schedule

Baseline (Before Starting CPA)

Follow-Up Schedule

12. Cost and Availability

Geographic Availability

Not Available in United States:

• Never FDA-approved
• Cannot be legally prescribed in US
• Some patients obtain from international pharmacies

Available in Most Other Countries:

• Europe (with restrictions since 2020)
• Canada
• Australia
• Latin America
• Asia
• Africa

Generic Availability

Generic Status:

• Original patent expired
• Generic versions available in most countries
• Multiple manufacturers globally

Cost (Approximate, Outside US):

• Androcur 50 mg: $0.50-2.00 per tablet
• Generic 50 mg: $0.20-1.00 per tablet
• Diane-35: $15-40 per pack
• Varies significantly by country

Brand Name Products

Insurance Coverage (Outside US)

Coverage Status:

• Generally covered for approved indications
• May require prior authorization for high doses
• Transgender therapy: Variable coverage
• Hirsutism/acne: Often covered

Obtaining in United States

Legal Considerations:

• Not legally available for prescription
• Some patients obtain from:
  • Canadian pharmacies (personal import)
  • Online international pharmacies
  • Travel to other countries
• FDA personal import policy may apply
• Not recommended to circumvent regulations

Comparison with US Alternatives

13. Clinical Evidence Summary

Prostate Cancer Studies

Historical Evidence:

• One of first antiandrogens developed
• Effective for androgen deprivation
• 70-80% response rates historically
• Largely replaced by newer agents in many settings

Comparative Studies:

• Similar efficacy to other androgen deprivation
• More side effects than GnRH agonists alone
• Role as anti-flare agent when starting GnRH agonists

Hirsutism Evidence

Randomized Controlled Trials:

• Superior to placebo
• Comparable efficacy to spironolactone
• 50-100 mg/day effective
• Diane-35 (2 mg) effective for mild-moderate cases

Meta-Analyses:

• Confirmed efficacy for hirsutism
• No clear superiority between antiandrogens
• Combined therapy (CPA + OCP) commonly used

Transgender Medicine Evidence

Testosterone Suppression:

• 2024 study: Low dose (10-12.5 mg) as effective as standard dose
• Testosterone suppression to female range achieved
• Combination with estradiol synergistic

Comparative Data:

• More effective T suppression than spironolactone
• Via both AR blockade and gonadotropin suppression
• Depression concern vs. other antiandrogens

Meningioma Risk Studies

French Population Study (2020):

• 253,777 women exposed
• Dose-dependent risk confirmed
• 11-fold increase at cumulative dose 36-60g
• Led to EMA regulatory action

Meta-Analysis (2022):

• Confirmed dose-dependent association
• Risk begins at cumulative doses >12g
• Low-dose (1-2 mg) preparations not associated

Guidelines Incorporation

14. Comparison with Alternatives

Antiandrogen Comparison

Specific Comparisons

CPA vs. Spironolactone:

• CPA: More potent antiandrogen
• CPA: Better T suppression (antigonadotropic)
• CPA: More side effects (depression, meningioma)
• CPA: Not available in US
• Spironolactone: Fewer serious risks
• Spironolactone: Hyperkalemia concern

CPA vs. Bicalutamide:

• Bicalutamide: Pure AR antagonist (no T suppression)
• Bicalutamide: Available in US
• Bicalutamide: Lower hepatotoxicity than CPA
• CPA: Dual mechanism (AR + gonadotropin)
• CPA: More mood effects

CPA vs. GnRH Agonists:

• GnRH agonists: More complete T suppression
• GnRH agonists: Injectable (usually)
• CPA: Oral convenience
• CPA: Used with GnRH agonists for flare prevention

For Transgender Feminizing Therapy

For Hirsutism

First-Line Options (Outside US):

• CPA + OCP (Diane-35 or equivalent)
• Spironolactone + OCP

US Options:

• Spironolactone + OCP
• Finasteride (off-label)
• Eflornithine (topical)

15. Storage and Handling

Tablets

Storage:

• Store at controlled room temperature (15-30°C / 59-86°F)
• Protect from moisture
• Protect from light
• Keep in original container

Handling:

• Tablets may be split for dose adjustment
• Handle with care in reproductive-age settings
• Wash hands after handling

Combined Formulations (Diane-35)

Storage:

• Room temperature storage
• Keep in blister pack until use
• Protect from moisture and heat

Stability

Shelf Life:

• Typically 2-3 years (check packaging)
• Do not use after expiration date

Special Handling Considerations

Teratogenicity Warning:

• CPA is teratogenic
• Pregnant women should not handle crushed tablets
• Healthcare workers: Standard precautions
• Contraceptive counseling for patients

Disposal:

• Do not flush medications
• Return unused medication to pharmacy
• Standard pharmaceutical waste disposal

16. References

Primary Literature

1. Neumann F. The antiandrogen cyproterone acetate: discovery, chemistry, basic pharmacology, clinical use and tool in basic research. Exp Clin Endocrinol. 1994;102(1):1-32.

2. Weissmann A, et al. Cyproterone acetate and meningioma: nationwide cohort study. BMJ. 2021;372:n37.

3. Gava G, et al. Cyproterone acetate vs spironolactone for feminizing hormone treatment: a retrospective study. J Sex Med. 2020;17(6):1119-1127.

4. Meyer G, et al. Safety and rapid efficacy of guideline-based gender-affirming hormone therapy. J Clin Endocrinol Metab. 2020;105(7):e2483-e2493.

5. Effectiveness of low dose cyproterone acetate compared to standard dose in feminizing hormone treatment. Int J Transgender Health. 2024.

Regulatory Documents

6. European Medicines Agency. Restrictions in use of cyproterone due to meningioma risk. February 2020.

7. MHRA Drug Safety Update. Cyproterone acetate: new advice to minimise risk of meningioma. July 2020.

8. Medsafe (New Zealand). Cyproterone acetate and the risk of meningioma. September 2020.

Clinical Guidelines

9. Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2017;102(11):3869-3903.

10. Martin KA, Anderson RR, Chang RJ, et al. Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(4):1233-1257.

11. Cornforth RH, et al. Cyproterone acetate in the treatment of hirsutism. Br J Dermatol. 1987;116(2):227-232.

Pharmacology References

12. Raudrant D, Rabe T. Progestogens with antiandrogenic properties. Drugs. 2003;63(5):463-492.

13. Kuhl H. Pharmacology of progestogens. J Reprod Med. 1999;44(2 Suppl):219-226.

Safety Reviews

14. Gil M, et al. Risk of meningioma among users of high doses of cyproterone acetate as compared with the general population. Br J Clin Pharmacol. 2011;72(6):965-968.

15. Gava G, et al. Liver enzyme alterations in transgender patients treated with cyproterone acetate: a systematic review. J Sex Med. 2021;18(9):1513-1522.

Drug Information Resources

16. Cyproterone Acetate. In: Martindale: The Complete Drug Reference. London: Pharmaceutical Press; 2024.

17. Androcur (cyproterone acetate) [product monograph]. Bayer Inc.

18. Diane-35 (cyproterone acetate/ethinylestradiol) [product monograph]. Bayer Inc.

19. Cyproterone acetate. In: DrugBank Online. www.drugbank.com

20. Cyproterone Acetate - Wikipedia. https://en.wikipedia.org/wiki/Cyproterone_acetate

Document Metadata

Document Completion: 2025-12-26 Status: PAPER 54 OF 76 COMPLETE Next Paper: #55 - Bicalutamide

This document is part of the comprehensive HRT/hormone therapy research paper series for clinical reference.